Search

Your search keyword '"Grønbæk, H"' showing total 664 results
Start Over Author "Grønbæk, H"
664 results on '"Grønbæk, H"'

8. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional

Author

Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J, Wall N, Grønbæk H, Florholmen J, Öhberg A, and Granberg D

Subjects
Medicine (General), R5-920
Abstract

Viktor Johanson,1 Benedicte Wilson,2 Anna Abrahamsson,3 Constantin Jianu,4 Jan Calissendorff,5 Najme Wall,6 Henning Grønbæk,7 Jon Florholmen,8 Anders Öhberg,9 Dan Granberg101Department of Surgery, Sahlgrenska University Hospital, Göteborg, Sweden; 2Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark; 3Karolinska Institutet, Department of Hepatology, Karolinska University Hospital, Huddinge, Sweden; 4Department of Gastroenterology and Liver Disease, St Olav Hospital, Trondheim, Norway; 5Karolinska Institutet, Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Solna, Sweden; 6Department of Oncology, Linköping University Hospital, Linköping, Sweden; 7Department of Medicine V, Aarhus University Hospital, Aarhus, Denmark; 8Department of Gastroenterology and Nutrition, University Hospital of North Norway, Tromsø, Norway; 9Medical Department, Ipsen AB, Stockholm, Sweden; 10Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, SwedenBackground: Lanreotide Autogel® is supplied in prefilled syringes. Therefore, it is possible for patients with neuroendocrine tumors to use self-/partner-administered injections. The primary objective of this study was to assess the proportion of patients preferring self/partner injections over injections administered by health care professionals, and to describe the impact of self/partner administration on efficacy, safety, and costs.Methods: Of 62 eligible patients, 26 (42%) patients with neuroendocrine tumors treated with a stable dose of lanreotide Autogel 90 mg or 120 mg every 4 weeks agreed to participate in this Phase IV, international, open-label, crossover study, conducted at hospitals in Sweden, Norway, and Denmark. Patients were randomized to two blocks, starting with administration of lanreotide Autogel by either self/partner or a health care professional. Preference for injections administered by self/partner or health care professionals was measured, as well as efficacy, safety, and health care resource utilization (both direct and indirect costs).Results: Of 25 evaluable patients, 22 (88%) preferred self/partner injections, mainly because they experienced increased independence. Based on all patients asked to participate (n = 62), 35% preferred self/partner injections on a regular basis. There was no difference in efficacy or safety between the two administration blocks.Conclusion: Many patients with neuroendocrine tumors prefer self/partner injection of lanreotide Autogel, and are able to self/partner inject without any impact on efficacy or safety. This administration method seems to provide a good alternative for suitable patients to increase patient independence and reduce the number of clinic visits.Keywords: neuroendocrine tumors, carcinoid syndrome, self administration, somatostatin analogs, lanreotide

Published
2012

9. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figue and Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figue

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.

Published
2022

10. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figueroa, M.P. Hofmann, W.P. Petta, S. de Oliveira, C.P.M.S. Puri, P. Pan, C.Q. Rac, M. Ralston, J. Ramji, A. Razavi, H. Alvares-da-Silva, M.R. Roberts, S. Roden, M. Rose, T. Rouabhia, S. Rovere-Querini, P. Rowe, I.A. Sadirova, S. Salupere, R. Saparbu, T. Sayegh, R. Sebastiani, G. Seki, Y. Selmo, J. Serme, A.K. Shaw, J.E. Shenoy, T. Sheron, N. Shibolet, O. Silva, M. Skrypnyk, I. Socha, P. Soriano, J. Spearman, C.W. Sridharan, K. Suárez, J.J. Sheriff, D.S. Sung, K.-C. Swain, M. Tacke, F. Taheri, S. Tan, S.-S. Tapper, E.B. Yki-Järvinen, H. Thiele, M. Shawa, I.T. Tolmane, I. Torres, E.A. Trauner, M. Treeprasertsuk, S. Turcanu, A. Valantinas, J. Vesterhus, M. Waked, I. Wild, S.H. Willemse, J. Wong, R.J. Xanthakos, S. Young, D.Y. Yu, M.-L. Zheng, K.I. Zeybel, M. Zheng, M.-H. the NAFLD Consensus Consortium

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.

Published
2022

12. Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease

Author

Sandby, K. Geiker, N.R.W. Dalamaga, M. Grønbæk, H. Magkos, F.

Abstract

Purpose of Review: Understanding the effects of dietary manipulations on intrahepatic triglyceride (IHTG) balance will have important implications for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Recent Findings: Reducing calorie intake to induce weight loss is the most potent intervention to decrease IHTG. Carbohydrate restriction during the initial stages of weight loss may be particularly beneficial, but at later stages, the amount of weight loss predominates over diet composition. By contrast, during weight stability, restricting calories from fat seems to be optimal for depleting liver fat. The degree of dietary fat saturation and the glycemic index of the carbohydrate have inconsistent effects on IHTG. Recently, the matrix of some foods (e.g., dairy) has been inversely associated with NAFLD. Summary: Dietary macronutrients differ in their effects on liver fat depending on the energy balance and the matrix of the food in which they are consumed. Therefore, investigations into dietary approaches for managing NAFLD should shift their perspective from that of isolated nutrients to that of whole foods and diets and include useful mechanistic insights. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Published
2021

13. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women

Author

Norat, T, Dossus, L, Rinaldi, S, Overvad, K, Grønbæk, H, Tjønneland, A, Olsen, A, Clavel-Chapelon, F, Boutron-Ruault, M C, Boeing, H, Lahmann, P H, Linseisen, J, Nagel, G, Trichopoulou, A, Trichopoulos, D, Kalapothaki, V, Sieri, S, Palli, D, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, H B, Peeters, P H M, van Gils, C H, Agudo, A, Amiano, P, Ardanoz, E, Martinez, C, Quirós, R, Tormo, M J, Bingham, S, Key, T J, Allen, N E, Ferrari, P, Slimani, N, Riboli, E, and Kaaks, R

Published
2007
Full Text
View/download PDF

17. 1160O An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis

Author

Nicolas, G.P., primary, Ansquer, C., additional, Lenzo, N.P., additional, Grønbæk, H., additional, Haug, A., additional, Navalkissoor, S., additional, Beauregard, J-M., additional, Germann, N., additional, McEwan, S., additional, Wild, D., additional, and Hicks, R.J., additional

Published
2020
Full Text
View/download PDF

20. Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer (Protocol)

Author

Lund, M, Nadarevic, T, Bjerre, TA, Grønbæk, H, Mortensen, F, and Kragh, Andersen P

Subjects
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti, colorectal cancer
Abstract

This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows: To determine the diagnostic accuracy of contrast- enhanced ultrasound (CEUS) versus contrast- enhanced computed tomography (CECT), magnetic resonance imaging (MRI), and fluro-18- deoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for diagnosing liver metastases in people with newly diagnosed colorectal cancer. Secondary objectives We plan to investigate the following potential sources of heterogeneity. • Study design (prospective compared to retrospective) • Study date (studies conducted before the year 2000 compared to studies conducted aMer the year 2000) due to advancements in technology and change in diagnostic criteria • Participant selection (participants recruited from planned screening programmes compared to clinical setting) • Proportion of participants with resectable liver metastasis • Maximum diameter of the largest liver lesion • DiNerences in operator skills in CEUS performance, assessed by years of experience • DiNerent reference standards (studies using pathology of resected liver compared to studies using histology of hepatic lesion)

Published
2020

29. FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis

Author

Bossen, L, Rebora, P, Bernuzzi, F, Aloise, C, Jepsen, P, Gerussi, A, Møller, H, Valsecchi, M, Carbone, M, Grønbæk, H, Invernizzi, P, Bossen, Lars, Rebora, Paola, Bernuzzi, Francesca, Aloise, Chiara, Jepsen, Peter, Gerussi, Alessio, Møller, Holger Jon, Valsecchi, Maria Grazia, Carbone, Marco, Grønbæk, Henning, Invernizzi, Pietro, Bossen, L, Rebora, P, Bernuzzi, F, Aloise, C, Jepsen, P, Gerussi, A, Møller, H, Valsecchi, M, Carbone, M, Grønbæk, H, Invernizzi, P, Bossen, Lars, Rebora, Paola, Bernuzzi, Francesca, Aloise, Chiara, Jepsen, Peter, Gerussi, Alessio, Møller, Holger Jon, Valsecchi, Maria Grazia, Carbone, Marco, Grønbæk, Henning, and Invernizzi, Pietro

Published
2019

32. Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome

Author

Rainer, F., primary, Horvath, A., additional, Bashir, M., additional, Leber, B., additional, Schmerboeck, B., additional, Blesl, A., additional, Madl, T., additional, Klymiuk, I., additional, Groselj-Strele, A., additional, Durdevic, M., additional, Grønbæk, H., additional, Møller, H.J., additional, Freedber, D.E., additional, Abrams, J.A., additional, Stauber, R.E., additional, Fickert, P., additional, Stiegler, P., additional, and Stadlbauer, V., additional

Published
2018
Full Text
View/download PDF

34. Epigenetic modification of urea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches

Author

De Chiara, F., primary, Jalan, R., additional, Marrone, G., additional, Heeboll, S., additional, Montoliu, C., additional, Hamilton-Dutoit, S., additional, García-Torres, M., additional, Andreola, F., additional, Rombouts, K., additional, Grønbæk, H., additional, Felipo, V., additional, Mookerjee, R., additional, and Louise Thomsen, K., additional

Published
2018
Full Text
View/download PDF

35. Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients

Author

Laursen, T.L., primary, Kazankov, K., additional, Sandahl, T.D., additional, Møller, H.J., additional, Hagelskjær Kristensen, L., additional, Holmboe, C., additional, Sølund, C., additional, Arildsen, H., additional, Laursen, A., additional, and Grønbæk, H., additional

Published
2018
Full Text
View/download PDF

36. Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections

Author

Fernandez, J., primary, Angeli, P., additional, Trebicka, J., additional, Merli, M., additional, Gustot, T., additional, Alessandria, C., additional, Aagaard, N.K., additional, De Gottardi, A., additional, Zeuzem, S., additional, Gerbes, A., additional, Soriano, G., additional, Vargas, V., additional, Albillos, A., additional, Salerno, F., additional, Durand, F., additional, Bañares, R., additional, Stauber, R.E., additional, Prado, V., additional, Arteaga, M., additional, Morando, F., additional, Jansen, C., additional, Lattanzi, B., additional, Moreno, C., additional, Risso, A., additional, Grønbæk, H., additional, Garcia, R., additional, Pavesi, M., additional, and Arroyo, V., additional

Published
2018
Full Text
View/download PDF

37. A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

Author

Dam, G., Grønbæk, H., Sørbye, H., Thiis-Evensen, E., Paulsson, B., Sundin, Anders, Jensen, C., Ebbesen, D., Knigge, U., Tiensuu Janson, Eva, Dam, G., Grønbæk, H., Sørbye, H., Thiis-Evensen, E., Paulsson, B., Sundin, Anders, Jensen, C., Ebbesen, D., Knigge, U., and Tiensuu Janson, Eva

Abstract

Meeting Abstract: F05

Published
2018
Full Text
View/download PDF

38. Intravenous versus Oral Etoposide:Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Author

Ali, A. A., Gronberg, M., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Langer, S. W., Welin, S., Vestermark, L. W., Osterlund, P., Knigge, U., Sorbye, H., Janson, E. T., Ali, A. A., Gronberg, M., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Langer, S. W., Welin, S., Vestermark, L. W., Osterlund, P., Knigge, U., Sorbye, H., and Janson, E. T.

Published
2018

42. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation

Author

Rainer, F., primary, Horvath, A., additional, Sandahl, T. D., additional, Leber, B., additional, Schmerboeck, B., additional, Blesl, A., additional, Groselj-Strele, A., additional, Stauber, R. E., additional, Fickert, P., additional, Stiegler, P., additional, Møller, H. J., additional, Grønbaek, H., additional, and Stadlbauer, V., additional

Published
2017
Full Text
View/download PDF

43. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Author

Galleberg, R.B., primary, Knigge, U., additional, Tiensuu Janson, E., additional, Vestermark, L.W., additional, Haugvik, S.-P., additional, Ladekarl, M., additional, Langer, S.W., additional, Grønbæk, H., additional, Österlund, P., additional, Hjortland, G.O., additional, Assmus, J., additional, Tang, L., additional, Perren, A., additional, and Sorbye, H., additional

Published
2017
Full Text
View/download PDF

47. This title is unavailable for guests, please login to see more information.

Author

Eslam, M, McLeod, D, Kelaeng, KS, Mangia, A, Berg, T, Thabet, K, Irving, WL, Dore, GJ ; https://orcid.org/0000-0002-4741-2622, Sheridan, D, Grønbæk, H, Abate, ML, Hartmann, R, Bugianesi, E, Spengler, U, Rojas, A, Booth, DR, Weltman, M, Mollison, L, Cheng, W, Riordan, S, Mahajan, H, Fischer, J, Nattermann, J, Douglas, MW, Liddle, C, Powell, E, Romero-Gomez, M, George, J, Metwally, M, White, R, Gallego-Duran, R, Leung, R, Mahajan, N, Bassendine, M, Rahme, A, Rosso, C, Mezzabotta, L, Malik, B, Matthews, G ; https://orcid.org/0000-0002-1048-6396, Asimakopoulos, A, Applegate, T, Grebely, J ; https://orcid.org/0000-0002-1833-2017, Fragomeli, V, Jonsson, JR, Santoro, R, Eslam, M, McLeod, D, Kelaeng, KS, Mangia, A, Berg, T, Thabet, K, Irving, WL, Dore, GJ ; https://orcid.org/0000-0002-4741-2622, Sheridan, D, Grønbæk, H, Abate, ML, Hartmann, R, Bugianesi, E, Spengler, U, Rojas, A, Booth, DR, Weltman, M, Mollison, L, Cheng, W, Riordan, S, Mahajan, H, Fischer, J, Nattermann, J, Douglas, MW, Liddle, C, Powell, E, Romero-Gomez, M, George, J, Metwally, M, White, R, Gallego-Duran, R, Leung, R, Mahajan, N, Bassendine, M, Rahme, A, Rosso, C, Mezzabotta, L, Malik, B, Matthews, G ; https://orcid.org/0000-0002-1048-6396, Asimakopoulos, A, Applegate, T, Grebely, J ; https://orcid.org/0000-0002-1833-2017, Fragomeli, V, Jonsson, JR, and Santoro, R

Published
2017

48. Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas:A Nordic Multicenter Study

Author

Galleberg, R. B., Knigge, U., Janson, E. T., Vestermark, L. W., Haugvik, S. P., Ladekarl, M., Langer, S. W., Grønbæk, H., Osterlund, P., Hjortland, G., Assmus, J., Tang, L., Perren, A., Sorbye, H., Galleberg, R. B., Knigge, U., Janson, E. T., Vestermark, L. W., Haugvik, S. P., Ladekarl, M., Langer, S. W., Grønbæk, H., Osterlund, P., Hjortland, G., Assmus, J., Tang, L., Perren, A., and Sorbye, H.

Published
2017

49. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Author

Galleberg, R B, Knigge, U, Tiensuu Janson, E, Vestermark, L W, Haugvik, S-P, Ladekarl, M, Langer, S W, Grønbæk, H, Österlund, P, Hjortland, G O, Assmus, J, Tang, L, Perren, A, Sorbye, H, Galleberg, R B, Knigge, U, Tiensuu Janson, E, Vestermark, L W, Haugvik, S-P, Ladekarl, M, Langer, S W, Grønbæk, H, Österlund, P, Hjortland, G O, Assmus, J, Tang, L, Perren, A, and Sorbye, H

Abstract

BACKGROUND: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Current international guidelines do not recommend surgical treatment of liver metastases, however the existing data are scarce. The aim of this study was to evaluate the results of curatively intended resection/radiofrequency ablation (RFA) of liver metastases in patients with metastatic GEP-NEC.METHODS: 32 patients with a diagnosis of high-grade gastroenteropancreatic neuroendocrine neoplasm (Ki-67 > 20%) and with intended curative resection/RFA of liver metastases, were identified among 840 patients from two Nordic GEP-NEC registries. Tumor morphology (well vs poor differentiation) was reassessed. Overall survival (OS) and progression-free survival (PFS) was assessed by Kaplan-Meier analyses for the entire cohort and for subgroups.RESULTS: Median OS after resection/RFA of liver metastases was 35.9 months (95%-CI: 20.6-51.3) with a five-year OS of 43%. The median PFS was 8.4 months (95%-CI: 3.9-13). Four patients (13%) were disease-free after 5 years. Two patients had well-differentiated morphology (NET G3) and 20 patients (63%) had Ki-67 ≥ 55%. A Ki-67 < 55% and receiving adjuvant chemotherapy were statistically significant factors of improved OS after liver resection/RFA.CONCLUSION: This study shows a long median and long term survival after liver surgery/RFA for these selected metastatic GEP-NEC patients, particularly for the group with a Ki-67 in the relatively lower G3 range. Our findings indicate a possible role for surgical treatment of liver metastases in the management of this patient population.

Published
2017

50. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk:results from the EPIC cohort, plus a meta-analysis of prospective studies

Author

Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Agnoli C, Palli D, Tumino R, Vineis P, Peeters PH, van Gils CH, Bueno de Mesquita BH, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer J, Borgquist S, Dumeaux V, Torhild Gram I, Lund E, Trichopoulou A, Makrygiannis G, Benetou V, Molina E, Donate Suárez I, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM, Olsen A, Tjonneland A, Grønbaek H, Overvad K, Clavel Chapelon F, Boutron Ruault MC, Morois S, Slimani N, Boffetta P, Jenab M, Riboli E, Kaaks R., PANICO, SALVATORE, Rinaldi, S, Cleveland, R, Norat, T, Biessy, C, Rohrmann, S, Linseisen, J, Boeing, H, Pischon, T, Panico, Salvatore, Agnoli, C, Palli, D, Tumino, R, Vineis, P, Peeters, Ph, van Gils, Ch, Bueno de Mesquita, Bh, Vrieling, A, Allen, Ne, Roddam, A, Bingham, S, Khaw, Kt, Manjer, J, Borgquist, S, Dumeaux, V, Torhild Gram, I, Lund, E, Trichopoulou, A, Makrygiannis, G, Benetou, V, Molina, E, Donate Suárez, I, Barricarte Gurrea, A, Gonzalez, Ca, Tormo, Mj, Altzibar, Jm, Olsen, A, Tjonneland, A, Grønbaek, H, Overvad, K, Clavel Chapelon, F, Boutron Ruault, Mc, Morois, S, Slimani, N, Boffetta, P, Jenab, M, Riboli, E, and Kaaks, R.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results